In a significant breakthrough, the National Institutes of Health (NIH) has reported that an experimental monoclonal antibody, L9LS, has shown promising results in preventing malaria in U.S. adults. The study, published in The New England Journal of Medicine, found that a single injection of L9LS was safe and highly protective in U.S. adults exposed to the malaria parasite.
NIH Trial Results
The NIH trial involved 18 volunteer participants who received various doses of L9LS subcutaneously or intravenously. The results showed that L9LS fully protected 15 of 17 (88%) participants from malaria infection during the 21-day challenge period.